India · Delayed Price · Currency is INR Sun Pharmaceutical Industries Earnings Call Transcripts
Fiscal Year 2026
-
Q4 FY 2026 saw 13.6% sales growth and strong gross margins, though EBITDA margin declined due to higher costs and lower milestone income. Innovative medicines drove growth globally, with India and emerging markets outperforming, while U.S. generics faced pressure. Organon acquisition integration is underway.
-
The acquisition will create a top 25 global pharma company with a strong presence in women's health, biosimilars, and innovative medicines, leveraging Organon's global footprint and Sun's execution capabilities. The $11.75B deal is expected to deliver $350M in cost synergies and be EPS accretive from year one.
-
Q3 FY2026 saw 15.1% sales growth and 16% net profit rise year-over-year, driven by strong India, emerging markets, and innovative medicine performance. Gross margin improved to 81%, and the company maintains a robust net cash position of $3.2 billion.
-
Q2 FY 2026 saw 8.6% sales growth, strong EBITDA and margin expansion, and robust innovative medicine performance, offset by U.S. generics decline. Cash position remains strong post-acquisitions, with continued R&D investment and new launches driving future growth.
-
Q1 FY 2026 saw 10.1% sales growth and 19.2% EBITDA growth, led by strong India and innovative medicines performance. U.S. business grew modestly, offset by generic pricing pressure, while new launches and a robust cash position support future investments. EBITDA margin reached 31.1%.
Fiscal Year 2025
-
FY25 saw 9% sales growth and 17% EBITDA growth, led by strong India and specialty business performance, while US generics faced pressure. FY26 guidance is for mid to high single-digit growth, with increased R&D and specialty launch investments.
-
Q3 FY25 saw 10.5% sales growth and 15.3% EBITDA growth year-over-year, with strong India and specialty segment performance. Adjusted net profit rose 24.1%, and the company maintained a $3 billion net cash position while increasing its interim dividend.
-
Q2 FY25 saw 10.5% revenue growth and 28% net profit increase, driven by strong India and U.S. performance, higher specialty sales, and robust R&D investment. Guidance for FY25 R&D spend is 7%-8% of sales, with continued focus on specialty pipeline and new launches.
-
Q1 FY 2025 saw 6.3% revenue growth and a 40.2% net profit increase year-over-year, with strong India and specialty sales offsetting a slight U.S. decline. Taro is now fully consolidated, and R&D spend is set to rise in coming quarters.